Overview

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Status:
RECRUITING

Trial end date:
2029-02-13

Target enrollment:

Participant gender:

Summary

This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period. Eligible participants may choose to continue treatment with fenebrutinib in the optional extension period after completing the dose exploration period.

Phase:

PHASE2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

fenebrutinib